Our Team

Roy is a board member at Averna Therapeutics and has served as a principal on the Private Equity team at OrbiMed since 2016. He previously led the merger, acquisition, and licensing efforts at Bayer HealthCare and Life Technologies (now Thermo Fisher Scientific).

He holds a PhD in molecular genetics from the Weizmann Institute and an MBA from the Wharton School of the University of Pennsylvania.